Articles tagged with Psoriasis
Researchers at the University of Birmingham have discovered a protein fragment called ?N-JARID2 that regulates skin cell differentiation. The finding holds promise for developing new gene therapies for psoriasis and other skin conditions caused by hyper-proliferation of skin cells.
Researchers have discovered a lipid called phosphatidylglycerol (PG) that may help restore healthy skin turnover in people with psoriasis. PG reduced inflammation and raised skin lesions when applied topically to a mouse model of psoriasis, suggesting it could be a new treatment option.
A new study found that inflammatory skin disorders like psoriasis increase the risk of type-2 diabetes. Improving skin health could be crucial for controlling blood sugar levels and reducing diabetes risk.
The LEO Foundation Skin Immunology Research Center will bring together leading researchers to provide new knowledge for better diagnoses and treatments of psoriasis and eczema. The center aims to strengthen the immune system's fight against over 3,000 known skin diseases.
Studies in mice with psoriasis-like conditions found that stiff blood vessel walls trapped cholesterol, promoting plaques and increasing cardiovascular risk. Neutralizing a specific immune cell type reduced collagen density and cholesterol deposits, suggesting a preventable link between autoimmune diseases and heart disease.
A multidisciplinary research team has provided fundamental new insight into the mechanism of dimethyl fumarate, a medical drug used to treat multiple sclerosis and psoriasis. The results describe an allosteric covalent inhibition of p90 ribosomal S6 kinases, pointing to an effective mechanism of kinase inhibition.
A new study published by the Keck School of Medicine of USC found that an online care delivery model is equivalent to in-person care for improving psoriasis symptoms. Patients with chronic skin diseases need ongoing care, and depending on where they live, their access to dermatological care can be variable.
A new study reveals pervasive stigmatizing views and myths about psoriasis in the United States, affecting daily life and relationships. The research found that 54% of respondents did not want to date someone with psoriasis, highlighting the need for education and awareness to dispel these negative perceptions.
Researchers found an inverse association between Mediterranean diet adherence and psoriasis severity, suggesting patients with severe psoriasis adhered less strongly to the diet. The study analyzed data from over 35,000 participants and used a scoring system to assess dietary adherence.
A Penn-led trial found that adalimumab, marketed as Humira, did not improve aortic vascular inflammation in psoriasis patients, but reduced markers of systemic inflammation and mild impairment in HDL function. The study suggests the drug may have cardiovascular benefits despite this finding.
A research team at UT Southwestern Medical Center has found that inhibiting glucose transport may be a safe and effective treatment for skin diseases like psoriasis. By targeting the metabolic requirements of hyperproliferative skin diseases, researchers were able to reduce disease-associated skin overgrowth and inflammation in mice.
A new study reveals that treating psoriasis with biologic therapy can significantly reduce coronary plaque. The research found that the treatments not only decreased plaque volume but also reduced inflammation, leading to fewer characteristics prone to rupture and cause a heart attack over time.
A compound derived from immune cells has been found to treat psoriasis in mice, with the potential to be effective against other autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The study suggests that the compound suppresses an inflammatory pathway that is overactive in these conditions.
Researchers found ustekinumab, used to treat psoriasis, also improves aortic inflammation, a key marker of cardiovascular risk. The drug resulted in a 19% improvement in aortic inflammation and significant reductions in skin inflammation.
A $6.5M NIH grant will support a Center of Research Translation in Psoriasis (CORT) at Case Western Reserve University. The CORT aims to advance translational discovery and application in psoriasis by integrating cutting-edge technology and bioinformatics with basic and clinical science.
Researchers found that normal tissue BRCA1 methylation is associated with an increased risk of high-grade ovarian cancer, which may occur as a prenatal event. The study analyzed white blood cells from patients and healthy controls and discovered that elevated BRCA1 methylation was confined to those diagnosed with high-grade serous tumors.
Researchers from the University of Pennsylvania found that black, Asian, and other non-Hispanic minorities are about 40% less likely to see a dermatologist for psoriasis than whites. Whites averaged double the number of doctor's appointments for psoriasis overall compared to non-Hispanic racial minorities.
Researchers found a strong connection between psoriasis severity and the risk of developing type 2 diabetes. Patients with more severe psoriasis are 64% more likely to develop diabetes than those without the condition.
The new American College of Rheumatology/National Psoriasis Foundation treatment guideline provides pharmacologic and non-pharmacologic recommendations for treating adult patients with active psoriatic arthritis. The guideline development team used the GRADE methodology to evaluate evidence and create therapy options.
Patients with psoriasis are at a higher risk of developing serious liver disease compared to those with rheumatoid arthritis, according to a large population-based study. The study found that systemic inflammation plays a significant role in the development of liver disease in these patients.
A group of inflammatory proteins called 'IL-36' play a significant role in the development of psoriasis and can be blocked without posing a risk to patients. The findings open up the possibility for new drugs to tackle this debilitating condition.
A researcher at the University of Pennsylvania will conduct a randomized, controlled study comparing home-based and office-based phototherapy treatments for psoriasis. The study aims to evaluate the effectiveness and safety of these treatments and fill an evidence gap in the treatment of this chronic autoimmune disease.
A study by Brigham and Women's Hospital researchers identifies a population of tissue resident memory cells that may be driving recurrence in psoriasis. These cells, which live long-term in the skin, can cause misguided immune responses leading to red, inflamed patches on the skin.
The PCORI Board approved funding for a new study comparing UVB treatment in a doctor's office versus at home for people with psoriasis. The study aims to improve treatment options for patients burdened by frequent in-office visits.
Researchers found that fire ant venom compounds can reduce skin thickening and inflammation in a mouse model of psoriasis. The solenopsin analogs, similar to ceramides, can restore the skin's barrier function and decrease immune cell infiltration.
Researchers found patients with psoriasis covering 10% or more of their body surface area are at almost double the risk of death. The study used an objective measure of disease severity to analyze the relationship between psoriasis severity and mortality.
Research suggests a connection between psoriasis and psychiatric illnesses, with inflammation being a key underlying factor. Psoriasis patients are at higher risk of anxiety, depression, and suicidal thoughts due to the debilitating nature of their condition.
A Swedish study found that biological treatments for psoriasis have a long-lasting positive impact on skin clearance and quality of life, even after switching between different medications. The study followed 583 individuals for up to 10 years and analyzed the effectiveness of treatments using three different measurements.
Two new drug classes, tofacitinib and guselkumab, have shown significant improvements in treating psoriatic arthritis. Tofacitinib demonstrated superiority over placebo in ACR20 response rates and HAQ-DI score at 3 months, while guselkumab improved joint symptoms, physical function, and quality of life in patients with active PsA.
A study of over 1,800 patients found that tildrakizumab significantly improved skin conditions in those with moderate-to-severe psoriasis. The treatment demonstrated a 75% improvement in PASI scores at 12 weeks, with fewer than 10% of placebo recipients showing similar results.
A new handheld scanner allows for non-invasive imaging of skin layers and blood vessels in psoriasis patients, enabling the assessment of disease severity and potential treatment options. The technology has the potential to improve diagnosis and therapy of other diseases such as skin cancer and diabetes.
Researchers found that HDAC3 inhibitors increase expression of aquaporin-3, a channel that transports glycerin, helping to improve skin health and reducing inflammation. The study's findings suggest that HDAC inhibitors could be an effective therapy for psoriasis.
Researchers have identified 16 new genetic markers associated with psoriasis, bringing the total to 63 loci linked to the disease. The largest psoriasis meta-analysis to date, involving over 39,000 participants, has shed light on pathways related to the disease and pinpointed potential gene targets.
Researchers at La Jolla Institute for Immunology pinpoint TWEAK as a common driver of skin inflammation in both diseases. The protein plays a major role in inducing pro-inflammatory signaling molecules that recruit immune cells to the skin.
Research from Umeå University found that women have a statistically significant lower incidence of severe psoriasis compared to men. Women with psoriasis had significantly lower median PASI values, indicating less severe disease.
A new study found that psoriasis patients who developed depression were 37% more likely to develop psoriatic arthritis compared to those without depression. This highlights the need for early detection and prevention of depression in psoriasis patients.
A study of 2,646 Swedish psoriasis patients found that nearly one in five still experienced high disease activity despite ongoing systemic treatment. The authors suggest increasing access to biologics and exploring new treatments, as well as supporting lifestyle improvements for better outcomes.
A study published in The American Journal of Clinical Nutrition found that weight loss reduced psoriasis severity and improved quality of life among obese test subjects. The results, which showed a lasting effect, underscore the importance of weight loss as part of a broader treatment regimen for overweight patients with psoriasis.
Researchers discovered that blocking IL-6 in psoriasis patients may not prevent skin inflammation, but its levels are central to thrombosis events triggered by skin inflammation. A compensatory 'workaround' mechanism involving other immune system molecules is proposed to explain the findings.
Researchers found that IL-12 has a positive effect on skin affected by psoriasis, preventing pathogenic immune cell infiltration and inhibiting inflammatory reactions. The current treatment ustekinumab neutralizes both IL-23 and IL-12, potentially leading to counterproductive effects.
Patients with moderate to severe psoriasis have similar coronary calcification as those with type 2 diabetes, both five times higher than in healthy controls. Early cardiovascular risk assessment is recommended for those with psoriasis due to increased atherosclerosis risk.
A Monash University and Harvard researchers have discovered the molecular cause of the itchy, painful rash caused by poison ivy. The finding identifies CD1a as a crucial immune molecule in mediating skin inflammation and irritation after contact with urushiol, a key player in triggering skin-based allergic reactions.
Researchers discovered that CD69 plays a key role in the development of psoriasis by regulating amino acid uptake and activation of inflammatory pathways. The study suggests that CD69 could serve as a future therapeutic target for treating this chronic inflammatory skin disease.
Researchers at Stanford University School of Medicine have identified Rac1 as a potential target for treating psoriasis. The small protein is involved in wound repair and has been linked to environmental triggers of the disease, as well as genetic predisposition. Blocking Rac1 activation may offer a new way to treat psoriasis without s...
A newly developed PsA-comorbidity index (PsACI) can identify PsA patients at greater risk of hospitalisation and premature death. The index is expected to improve patient outcomes and reduce costs.
A new drug called ixekizumab has shown significant promise in treating moderate to severe psoriasis, with 80 percent of patients experiencing complete or near-complete clearance of their symptoms. The long-term efficacy and safety of the treatment will be monitored closely.
Scientists discover B lymphocytes play a crucial role in psoriasis by regulating IL-10 levels, which can lead to poorer inflammatory control. This finding provides potential targets for new therapies to combat the incurable disease.
Researchers found that IL-17A stimulates skin cells to express genes maintaining an inflammatory microenvironment, leading to psoriasis. The study identified NFKBIZ gene as playing a significant role in the IL-17A pathway.
A study of 33,588 Danish twins found psoriasis associated with type 2 diabetes and obesity, with a possible common genetic cause. The prevalence of psoriasis was higher among individuals with obesity, suggesting a potential link between the two conditions.
Researchers have identified a molecular signaling mechanism underlying increased inflammation in patients with psoriasis due to specific CARD14 gene mutations. The study suggests MALT1 inhibitors may be therapeutically beneficial, offering promising results for treatment.
A new study found that Medicare patients with moderate to severe plaque psoriasis have low adherence to biologic therapies, with nearly half stopping treatment within a year. High out-of-pocket costs under Medicare Part D were identified as a potential factor contributing to this issue.
Researchers from CNIO have discovered a link between psoriasis and bone loss, finding that the disease causes widespread and progressive bone tissue loss. Treating psoriasis patients with IL-17 blockers could have benefits for bone health, and the study suggests potential implications for other autoimmune disorders.
A Swedish study found that psoriasis patients over 30 years old are 65% less likely to receive efficient treatment with biologics. Researchers analyzed health data from 1,465 patients and controlled for variables such as gender, BMI, and comorbidity.
Researchers developed molecular prosthetics that can detect complex signals in the immune system to suppress inflammatory responses. The prosthetics were implanted into mice and successfully treated psoriasis, providing a potential early-warning system for prevention.
A new study found that black patients receiving Medicare are less likely to receive biologic therapies for moderate to severe psoriasis than white patients, while those without low-income subsidy are also at a disadvantage. Psoriasis, a chronic inflammatory disorder, has limited therapeutic options due to high costs and limited insuran...
Researchers at NYU Langone Health found that bariatric surgery significantly reduced psoriasis and psoriatic arthritis symptoms in patients who lost excess weight. The study suggests that obesity contributes to the development of these conditions through systemic inflammation.
Research found that psoriasis patients had high levels of blood vessel inflammation, even at low cardiovascular risk. The most extensive forms of psoriasis were associated with a 51% increase in blood vessel inflammation.
A multicenter clinical trial led by Mount Sinai researchers found that brodalumab achieved a 100 percent reduction in psoriasis symptoms, exceeding the results of ustekinumab. The study demonstrated that targeting the IL-17 receptor is highly effective in treating moderate to severe plaque psoriasis.
A study published in JAMA Dermatology found that psoriasis is associated with a higher risk of major depression, regardless of severity. Patients with psoriasis reported daily functional impairment more frequently than those without the condition.
A new psoriasis drug called guselkumab has been shown to be more effective than the current standard of care in treating moderate-to-severe psoriasis. The study found that 81% of patients taking a 200-mg dose of guselkumab had cleared or minimal psoriasis after 40 weeks.